Monocyte and Macrophage Activation Measured in Biologic Fluids

Co-developed by the two companies the measures the amount of sCD levels in body fluids. sCD163 is a marker that enables quantification of monocyte and macrophage activation. IQ Products will market the Macro163 kit through its international sales and distribution network. Trillium will be responsible for the marketing and sales in North America.

"This fits perfectly in IQ Products' strategy to excel in perinatal and sepsis diagnostics. With the addition of the Macro163 sCD ELISA kit we have a premium new product to be used in a broad spectrum of research applications, like infection, with the exclusive rights to implement this as a future in vitro diagnostic product”, said Olf Boesjes MBA, general manager for IQ Products. "With the Macro163 sCD163 ELISA kit we emphasize the promise of becoming an important player in this field”.

Dr. Bruce H. Davis MD, founder and CEO of Trillium, added, "We are excited about this new joint product. This is the first milestone of our cooperation in developing new products around CD64 and CD163 testing, as well as new developments in the area of red cell testing.”

IQ Products is committed to bring innovative products to the market for research and diagnostics in human healthcare. The company's goal is to find new and innovative solutions especially in the perinatal and transplantation area.

Trillium Diagnostics is committed to improving healthcare by developing diagnostic assays in the area of laboratory hematology that are innovative, robust, and reliable. Product development is focused on novel cellular and molecular diagnostics in the detection of inflammatory related diseases and red cells for the assessment of feto-maternal hemorrhage and anemia evaluation.


Related Links:
IQ Products
Trillium Diagnostics